Late-stage clinical companies

Syncona’s late-stage clinical companies have advanced past Phase II clinical trials and are primed with a number of near-term value drivers.

Syncona has a world-leading late-stage clinical portfolio developing products with the potential to treat patients across a range of diseases including: leukaemia, lymphoma, multiple myeloma and X-linked retinitis pigmentosa.

The Syncona team has established and built fully integrated companies with best-in-class manufacturing capabilities and world-leading management teams across Syncona’s late-stage clinical companies.

Key facts

Unless stated all financials at 30 September 2023


Value of late-stage clinical portfolio


Number of clinical trials


Portfolio company Board seats

Our late-stage clinical companies

Late-stage clinical company pipeline